Celularity Inc. (CELU) stock forecast & analysis
1.97
NasdaqCM · USD
Down: -0.13, -6.2%
1 analysis
- Open
- 2.16
- Previous close
- 2.10
- Day range
- 1.85 – 2.20
- 52-week range
- 0.5600 – 4.00
- Volume (shares)
- 10.72M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 28.95M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.54
- Market cap
- 57.02M
Market Scanner’s AI analysis of Celularity Inc. (CELU), updated August 2026: Celularity's manufacturing collaboration and Nasdaq compliance update contrasted with declining revenue and negative margins.
Summary
Celularity's manufacturing collaboration and Nasdaq compliance update contrasted with declining revenue and negative margins.
Recent analyses covered Celularity's manufacturing collaboration with MuseCell Innovations, a potential $300 million deal, and progress on Nasdaq listing compliance. These developments were discussed alongside the company's financial performance, which showed a significant year-over-year revenue decline, negative profit margins, and negative shareholder equity.
CELU news & sentiment
News reports highlighted a significant manufacturing collaboration and progress on regulatory compliance. Social media discussions focused on the company's technical trading indicators, with strong buying pressure noted.
CELU technical picture
CELU's price action showed a strong uptrend, with the price well above both the 50-day and 200-day SMAs, and the 50-day SMA above the 200-day SMA. Momentum indicators like RSI and MFI were in overbought territory, suggesting extreme buying pressure, while the MACD indicated stabilizing momentum after a strong run. The price was also above the upper Bollinger Band.
Fundamentals
Revenue has declined significantly year-over-year, with negative profit and operating margins. The company also reported negative shareholder equity.
Factors discussed — upside
- Strong bullish trend indicated by SMAs and EMAs.
- Extremely high RSI and MFI signaling strong buying pressure.
- Manufacturing collaboration with MuseCell Innovations for the Dezawa MuseCell® Platform.
- Potential purchase opportunity valued at $300 million from MuseCell collaboration.
- Progress towards meeting Nasdaq listing requirements.
Factors discussed — risks
- Year-over-year revenue decline of 77.4% for the latest reported quarter.
- Negative profit margins (TTM profit margin 0%, operating margin TTM -4.92%).
- Negative total shareholder equity.
- Current price above the upper Bollinger Band, suggesting potential overextension.
- Market technicals
- Financial performance
- Strategic collaborations
- Regulatory compliance
Summary updated .
CELU technical indicators
Common technical indicators for CELU, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.78 | Price above |
| 10-day exponential moving average | 1.19 | Price above |
| Relative strength index (14-day) | 85.10 | Overbought |
| MACD line (12/26/9) | 0.1965 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.07 – 1.65 | Price above the upper band |
Analyses
Recent CELU.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Celularity Inc.?
- The bull case discussed Celularity's strong bullish technical trends, including significant price appreciation above key moving averages and extremely high RSI and MFI readings indicating intense buying pressure. The company's strategic manufacturing collaboration with MuseCell Innovations, potentially valued at $300 million, and progress on meeting Nasdaq listing requirements were also noted as positive developments.
- What are the risks for Celularity Inc.?
- The bear case highlighted Celularity's financial headwinds, including a substantial year-over-year revenue decline, negative profit and operating margins, and negative shareholder equity. Additionally, the current stock price trading above the upper Bollinger Band suggested a potential for overextension.
- Is Celularity Inc. bullish or bearish?
- Recent AI analyses of Celularity Inc. examined factors on both sides. Discussed upside: The bull case discussed Celularity's strong bullish technical trends, including significant price appreciation above key moving averages and extremely high RSI and MFI readings indicating intense buying pressure. The company's strategic manufacturing collaboration with MuseCell Innovations, potentially valued at $300 million, and progress on meeting Nasdaq listing requirements were also noted as positive developments. Discussed risks: The bear case highlighted Celularity's financial headwinds, including a substantial year-over-year revenue decline, negative profit and operating margins, and negative shareholder equity. Additionally, the current stock price trading above the upper Bollinger Band suggested a potential for overextension. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Celularity Inc.?
- News reports highlighted a significant manufacturing collaboration and progress on regulatory compliance. Social media discussions focused on the company's technical trading indicators, with strong buying pressure noted.
- Bundles used
- gemini-low-v2
Run a fresh CELU.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every CELU.US report already in the library